The mechanism for fetal heart rate abnormalities following spinal opioids remains controversial. We evaluated uterine tone, using an intra-uterine pressure catheter, and fetal heart rate abnormalities in 30 women in spontaneous labour with cervical dilation of 3-5 cm having combined spinal-epidural analgesia. Women were randomly assigned to receive a spinal with 2.0 mg hyperbaric bupivacaine plus 15 lg fentanyl, or 2.5 mg hyperbaric bupivacaine. The primary outcome measure was an increase > 10 mmHg in baseline uterine tone in the 30-min period following spinal injection. Only three (20%) women who had a bupivacaine-fentanyl spinal showed a > 10 mmHg increase in baseline tone vs. none who had bupivacaine (p = 0.63). The mean (SD) baseline uterine tone after the spinal injection was 13.3 (7.0) mmHg in the bupivacaine-fentanyl group and 7.7 (2.5) mmHg in the bupivacaine group (p = 0.01). Seven (47%) in the bupivacaine-fentanyl group showed new onset fetal heart rate changes during the 30-min period after the spinal, compared with two (13%) in the bupivacaine group (p = 0.04); however, these were transient and responded to intra-uterine resuscitation. Pain scores, sensory and motor block as well as neonatal outcomes were comparable between the groups. We found that raised baseline uterine tone was not more frequent when using bupivacaine-fentanyl rather than bupivacaine in the spinal component of combined spinal-epidural, although absolute values of baseline tone were higher, and fetal heart rate changes more frequent, in the former group.
Introduction
Combined spinal-epidural (CSE) analgesia is a technique that provides rapid and effective analgesia during labour, with minimal motor impairment and high maternal satisfaction [1] [2] [3] . Despite these advantages, a high incidence of fetal heart rate (FHR) abnormalities, ranging between 4% and 21%, and uterine hyperactivity have been reported with its use [3] [4] [5] [6] [7] [8] . The exact cause of FHR changes after CSE analgesia remains controversial [9] . One suggested mechanism is that rapid onset of effective pain relief causes a reduction in maternal circulating catecholamines, leading to uterine hyperactivity and reduced uternoplacental blood flow [9, 10] . This hypothesis has usually been tested with external tocography to assess uterine activity [11, 12] . Abrao et al. used intra-uterine pressure monitoring to compare CSE and epidural analgesia [13] , and reported CSE and increased baseline uterine tone (i.e. between contractions) as independent predictors of FHR abnormalities. However, their two analgesic regimens were not equipotent, as women in the epidural group had higher pain scores [14] .
Clarke et al. were the first to find an association between spinal opioids and uterine hyperactivity [10] . Thereafter, several retrospective trials reported a correlation between spinal opioids and FHR changes [4, 5, 7, 11] . In a prospective study, van de Velde et al. linked FHR abnormalities and uterine hyperactivity to the central release of oxytocin and vasopressin induced by spinal opioids [12] . However, it is still unclear whether the CSE technique, or opioids in the spinal component of CSE, accounts for uterine hyperactivity and FHR changes.
Loubert et al. wrote "Are spinal opioids really indicated in combined spinal-epidural analgesia?" [15] , as spinal bupivacaine alone might provide acceptable maternal analgesia without significant motor blockade, hypotension and FHR changes. The present study assessed the difference between spinal bupivacainefentanyl or bupivacaine on baseline uterine tone and FHR abnormalities; our hypothesis was that the use of fentanyl would be associated with higher uterine tone.
Methods
We obtained Institutional Ethics Committee approval to conduct this prospective, double-blind, randomised trial in the maternity wing of our tertiary care hospital. Low-risk women between 36 weeks and 42 weeks gestation with a singleton vertex fetus pregnancy were assessed for eligibility in the labour room. Women, who were in active labour between 3 cm and 5 cm cervical dilation, and requested regional analgesia, were approached to participate in the study; if in agreement, we obtained written informed consent. Exclusion criteria included: already had other analgesia; contraindications to regional analgesia; breech presentation; pre-labour rupture of membranes; maternal pyrexia > 38°C; uterine scarring; diabetes mellitus; hypertensive disorders; severe anaemia (Hb < 8 g.dl
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); cardiac disease; severe fetal growth restriction (estimated fetal weight < 2 SD for gestational age); severe oligohydramnios (amniotic fluid index < 5); and fetal umbilical artery Doppler abnormalities.
The use of a visual analogue scale (VAS), where 0 = no pain and 10 = worst possible pain, was explained to all women, and they graded the pain of contractions.
Women were transferred to the operating room for insertion of the intra-uterine pressure catheter and to establish CSE. Intravenous (i.v.) access was secured with an 18-G cannula, and 500 ml Ringer's lactate solution was administered intravenously. Non-invasive monitoring was established. Randomisation was performed using a computer program (http://www.rand omiser.org), and concealment was ensured using sequentially numbered sealed envelopes. A researcher (KJ), who was not involved in further data collection, opened the appropriate envelope and prepared the spinal drug mixture. For the bupivacaine-fentanyl group, 2.0 mg of hyperbaric bupivacaine 0.5% (0.4 ml) plus 15 lg fentanyl (0.3 ml withdrawn from a 1-ml tuberculin syringe) plus 0.2 ml saline was drawn up. For the bupivacaine group, 2.5 mg of hyperbaric bupivacaine 0.5% (0.5 ml) plus 0.5 ml saline was drawn up, to give the same 1-ml volume.
Using sterile precautions, an obstetrician ruptured the membranes and inserted the intra-uterine pressure catheter to the 45-cm mark (Intran Plus IUP-400 with regular size tip; Utah Medical Products Inc., Midvale, UT, USA). This was connected to a Sonicaid TM FM800 Encore (Huntleigh Healthcare Ltd, Cardiff, UK), and the catheter zeroed using the inbuilt switch. The cardiotocograph (CTG) was monitored for 15 min in the supine position. An anaesthetist (AK/JM) who was blinded to group allocation then performed the CSE in the left lateral position using an Espocan â set (B Braun
Ltd, Melsungen, Germany). Using a midline approach, the L3-4 epidural space was identified with an 88-mm 18-G Pencan â Tuohy needle with loss-of-resistance to saline. A 139-mm 27-G pencil point Pencan needle was passed through the Tuohy needle. After free flow of cerebrospinal fluid was obtained, the spinal injection was performed and a multi-orifice epidural catheter threaded 3-4 cm into the epidural space. The women were turned supine, with a wedge providing left uterine displacement. Cardiovascular measurements and VAS scores were taken at 1-min intervals after the spinal for 5 min, and then 5-min intervals for 30 min. Hypotension, defined as systolic arterial pressure < 80% baseline, was treated with 50 lg phenylephrine boluses. Sensory block height was assessed by noting any change in cold sensation to ice. Motor block was assessed using the modified Bromage scale [16] at 5-min, 15-min and 30-min intervals.
After the 30-min monitoring period was completed, the women returned to their labour room. Epidural analgesia was commenced at this point using a 6-8 ml bolus of 0.1% bupivacaine plus 2 lg.ml fentanyl, followed by a continuous infusion at 6-8 ml.hr À1 using a syringe pump (Syringe Pump 950;
EMCO Meditek â Pvt. Ltd, Baroda, India). Rescue boluses of 5-10 ml of the same solution were used to keep the VAS score ˂ 3. Episodes of suspicious or pathological CTG traces were managed according to the National Institute for Health and Care Excellence guidelines that were current at the time of the study [17] . Conservative measures of intra-uterine fetal resuscitation were carried out for a suspicious trace, and delivery was expedited for a pathological trace or if conservative measures failed. Umbilical artery and vein samples were analysed after delivery. An obstetrician (RB), blinded to group allocation, analysed the CTG for the 15-min period before and 30 min after the spinal injection.
The primary outcome of the study was to detect whether there was an increase in the incidence of raised baseline uterine tone > 10 mm Hg in the 30-min period following CSE. Using the data of Abrao et al. [13] , we calculated the sample size required to detect a difference of 40% between groups in the incidence of raised tone; 15 women were needed in each arm for statistical significance, with a power of 85% and significance level of 5%.
Distribution of data was tested for normality using the Kolmogorov-Smirnov test. Baseline uterine tone and FHR abnormalities were analysed using independent samples t-test and Chi-square test, as appropriate. Intergroup comparison of VAS scores was performed using the Mann-Whitney test, and ANOVA was used to compare baseline VAS to VAS after CSE. All other secondary outcomes were analysed using unpaired t-tests, Mann-Whitney test, ANOVA and Chi-square tests, as appropriate. Analysis was done using Statistics for Windows version 10.0 software (SPSS Inc., Chicago, IL, USA). A value of p < 0.05 was considered as statistically significant. Figure 1 shows the CONSORT recruitment diagram. Final data on 30 women were analysed. Maternal physical characteristics were comparable between both groups (Table 1) .
Results
Three (20%) women in the bupivacaine-fentanyl group had a > 10 mmHg increase in baseline tone during the 30-min period after CSE, compared with none in the bupivacaine group (p = 0.63). The mean (SD) baseline uterine tone before the CSE was 11.6 (6.5) mmHg in the bupivacaine-fentanyl group and 10.0 (8.5) mmHg in the bupivacaine group (p > 0.05); after CSE it was 13.3 (7.0) mmHg and 7.7 (2.5) mmHg, respectively (p = 0.01).
Seven (47%) women in the bupivacaine-fentanyl group showed new onset FHR changes during the 30-min period after the spinal, compared with two (13%) in the bupivacaine group (p = 0.04; Table 2 ). All these women responded to intra-uterine resuscitation with left lateral positioning, administration of 100% oxygen, i.v. fluid and phenylephrine, without requiring tocolysis.
Eight of these nine women delivered normally, and their neonates had good Apgar scores. One woman in the bupivacaine-fentanyl group had two episodes of late decelerations during the study period that normalised after 15 min (Table 2) . Six hours later, the CTG showed repetitive late decelerations requiring an emergency caesarean section, when a tight loop of umbilical cord was discovered round the baby's neck. Another woman in the bupivacaine-fentanyl group had preparations made for caesarean section when the FHR showed a prolonged deceleration lasting for 8 min, followed by reduced baseline variability for 13 min. However, the abnormalities resolved and she had a normal delivery 4 h later.
There was a significant decrease in VAS scores compared with baseline at all time intervals in both groups (p < 0.05), but there was no difference between groups (Fig. 2) . Four (27%) women in each group had hypotension. Sensory and motor block were similar between groups. No women developed nausea or vomiting. Four women developed pruritus in the bupivacaine-fentanyl group vs. none in the bupivacaine group (p = 0.03). There were no differences in umbilical artery and vein blood gases between groups. All neonates had normal Apgar scores, and no neonates required resuscitation or intensive care admission.
Discussion
Our study found a higher incidence of increased baseline uterine tone and FHR abnormalities after spinal with bupivacaine-fentanyl compared with bupivacaine alone. The FHR abnormalities were either minor or resolved rapidly. The incidence of hypotension was similar in both the groups.
The links between spinal (CSE) analgesia, uterine activity and FHR changes remain unclear. Abrao et al. concluded that CSE analgesia is an independent predictor of increased baseline uterine tone ≥ 10 mmHg, with an OR of 3.5 vs. epidural, as well as more frequent FHR abnormalities. They also demonstrated that pain relief at 5 min independently predicted a combination of FHR abnormalities and increased baseline uterine tone, with an OR of 0.77 [13] . In correspondence, Landau et al. suggested that the findings might be ascribed to a difference in the intensity of analgesia following different techniques, rather than to the CSE technique per se [14] .
Meta-analysis has suggested an increased risk of fetal bradycardia [18] and a non-reassuring FHR trace [19] related to the spinal opioid, after a sudden decrease in plasma adrenaline and b-endorphins but unchanged noradrenaline and oxytocin [20] . Patel et al. found no difference in FHR abnormalities when labour analgesia was initiated with CSE using spinal 2.5 mg bupivacaine plus 5 lg fentanyl compared with 20 ml epidural bupivacaine 0.1% plus fentanyl 2 lg.ml
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. They reported that maternal hypotension, parity and efficacy of analgesia did not contribute to non-reassuring FHR patterns, and suggested that nonreassuring FHR patterns might result from exogenous oxytocin administration [21] . However, it was also proposed that the low fentanyl dose was a factor tending to reduce any difference between groups [22] .
The necessity of using spinal opioids to initiate CSE analgesia has been questioned [15, 23] . Combining bupivacaine with fentanyl for spinal analgesia in labour is usual, but commonly used doses may be excessive. The minimum local analgesic dose of spinal bupivacaine during the first stage of labour was found to be 1.99 mg, with the addition of 5 lg, 15 lg or 25 lg of fentanyl resulting in a similar significant bupivacaine-sparing effect and dose-dependent prolongation of analgesia [24] ; it was calculated as 2.37 mg in a subsequent investigation [25] . We chose a reduced dose of 2 mg bupivacaine, with a lower dose of 15 lg fentanyl, to reduce the risk of FHR changes associated with a higher dose [18, 19, 23] .
We chose to use hyperbaric bupivacaine as Rofaeel et al. found that isobaric bupivacaine produced faster onset of labour analgesia, higher sensory levels and less motor block than hyperbaric bupivacaine, but at the expense of more pruritus, hypotension and sustained fetal bradycardia [26] . Pruritus in the bupivacainefentanyl group was frequent, but transient and resolved without treatment. Besides the analgesic technique or drugs, factors suggested in the development of FHR changes after CSE include older maternal age and higher pain scores [27] , non-engagement of the fetal head in the pelvis [28] , parity, use of oxytocin [21] and initiation of analgesia late in labour [13] . Our study groups were balanced with regard to parity, cervical dilation and VAS scores, and we did not include women receiving oxytocin for induction or augmentation of labour.
The clinical relevance of FHR abnormalities after CSE is controversial. Mardirosoff et al. did not find a significant clinical effect of spinal opioids on 5-min Apgar scores or instrumental delivery and caesarean section rates; similarly van de Velde et al. reported that none of the non-reassuring FHR patterns in their trial resulted in serious maternal or neonatal morbidity [18, 23] . However, Clarke et al. and Cortes et al. both reported two women requiring emergency caesarean section for persistent fetal bradycardia, associated with raised uterine tone [10, 29] . In our study, FHR changes were transient in nature and responded to intra-uterine resuscitation measures of maternal positioning, supplemental oxygen and i.v. fluid and vasopressor administration. The incidence of caesarean section and neonatal outcomes were comparable in both groups.
In conclusion, CSE analgesia may be associated with raised baseline uterine tone and FHR changes. This has implications for patient selection and ongoing fetal monitoring. Spinal hyperbaric bupivacaine offers similar pain relief compared with a hyperbaric bupivacaine-fentanyl combination, with a lower incidence of FHR abnormalities. Additional larger studies using intra-uterine pressure measurements are indicated. 
